Clinical trials
Prostate clinical trials
Below are recruiting prostate clinical trials, each written for real people, not researchers. We’re tracking 1,373 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06335693Recruiting
Short-course radiation after prostate surgery
This trial tests a shorter course of radiation therapy (hypofractionated radiotherapy) for men who have already had their prostate removed and still have signs of cancer (like rising PSA). The goal is to see if this can help prevent the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06343077RecruitingPhase 2
Hiltonol injection for prostate cancer on active surveillance
This trial tests a drug called Hiltonol (Poly-ICLC) given directly into the prostate tumor along with an injection under the skin. It is for men with low-risk prostate cancer who are on active surveillance, to see if the drug can slow or stop the cancer from growing.
New York, New YorkAges 18 years+ - NCT06347705RecruitingPhase 2
Vaccine plus standard therapy for prostate cancer before surgery
This trial tests an experimental vaccine (2141-V11) combined with standard hormone therapy and an anti-androgen drug before prostate removal surgery. It aims to see if the combination can help the immune system fight the cancer more effectively.
Basking Ridge, New JerseyAges 18 years+ - NCT06353386RecruitingPhase 1/Phase 2
Opevesostat combinations for advanced prostate cancer
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06355050Recruiting
Short, intense radiation for prostate cancer
This trial tests a very short course of daily radiation that adapts to your body's changes. It aims to be just as effective as standard treatment but more convenient.
JenaAges 18–120 - NCT06355336Recruiting
Prostate cancer registry for men in the Ohio region
This trial is a registry that collects information from men with prostate cancer to help doctors learn more about the disease and improve care. It is open to people recently diagnosed (since 2023) who live in Ohio, Kentucky, or Indiana.
Cincinnati, OhioAges 18 years+ - NCT06360523Recruiting
AI-guided MRI for prostate cancer diagnosis
This trial tests if an artificial intelligence system can improve MRI scans used to detect prostate cancer. You may join if your doctor has recommended a prostate biopsy and you have an MRI scan that can be reviewed by both radiologists and AI.
Hong KongAges 18 years+ - NCT06363266Recruiting
Tempo program for men with prostate cancer and their caregivers
This study tests a program called TEMPO to help men with prostate cancer and their caregivers manage anxiety. You and your chosen caregiver will use an online tool designed to support your well-being.
Montreal, CanadaAges 18 years+ - NCT06378346RecruitingPhase 2
Glycyrrhizin for prostate cancer before surgery
This trial tests a natural substance called glycyrrhizin (found in licorice root) before prostate surgery. It aims to see if it can help control prostate cancer. You would take it for a short time before your planned prostate removal.
Chicago, IllinoisAges 18 years+ - NCT06385977Recruiting
Risk Factors for Chronic Prostatitis in Northwest China
This study looks for risk factors in men from Northwest China with long-term pelvic or perineal pain (chronic prostatitis) compared to healthy volunteers.
Xi'an, ShaanxiAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT06397703RecruitingPhase 2
Testosterone Blockers and Radiation for Prostate Cancer
This trial tests whether adding hormone therapy (ADT) to stereotactic body radiation therapy (SBRT) works better than SBRT alone for men with a specific type of prostate cancer called 'unfavorable intermediate risk.' The goal is to see if the combination helps control the cancer better.
New York, New YorkAges 18 years+ - NCT06398639Recruiting
Using genetic risk and MRI to find dangerous prostate cancer
This study uses a genetic risk score and a special MRI scan to find prostate cancers that are more likely to be dangerous. It aims to see if combining these tests can better identify which men need a biopsy.
Washington D.C., District of ColumbiaAges 40–69 - NCT06402357RecruitingPhase 2
Focused Ultrasound for Recurrent Prostate Cancer After Radiation
This trial tests if a focused ultrasound treatment can safely and effectively treat prostate cancer that has come back after radiation therapy. The ultrasound uses sound waves to heat and destroy cancer cells in a specific area of the prostate while sparing healthy tissue.
Gainesville, FloridaAges 18 years+ - NCT06406803Recruiting
Exercise vs. diet for prostate cancer patients before surgery
This study compares the effects of exercise and a low-calorie diet on how your body builds proteins in your tumor and muscles. It may help men with prostate cancer who are about to have surgery.
HasseltAges 18 years+ - NCT06422455Recruiting
Genetic testing for underserved cancer patients
This study offers free genetic testing to cancer patients and their healthcare providers. It aims to help people who may not have easy access to genetic testing understand their cancer risk.
Los Angeles, CaliforniaAges 18 years+ - NCT06437574RecruitingPhase 2
Cholesterol-lowering and immune response in prostate cancer
This trial tests whether taking a daily cholesterol-lowering medication (Vytorin or ezetimibe) can boost your immune system to help fight prostate cancer. It is for men with low- or intermediate-risk prostate cancer who are on active surveillance and planning a biopsy.
Los Angeles, CaliforniaAges 18 years+ - NCT06446401Recruiting
Triple vs double therapy for widespread prostate cancer
This trial compares two treatment approaches for men whose prostate cancer has spread widely and is still responding to hormone therapy. It tests whether using three drugs together (triple therapy) works better than two drugs (double therapy) to control the cancer longer.
Uppsala, Region UppsalaAges 18 years+ - NCT06449781RecruitingPhase 2
177Lu-PSMA after surgery or radiation for high-risk prostate cancer
This study tests a new treatment called 177Lu-PSMA given after standard therapy (surgery or radiation) to see if it can prevent prostate cancer from coming back. It is for patients with high or very high-risk prostate cancer that hasn't spread yet.
GliwiceAges 18 years+ - NCT06451445Recruiting
Focal IRE treatment for intermediate-risk prostate cancer
This trial tests a new focal treatment called IRE (irreversible electroporation) that uses electrical pulses to destroy prostate cancer cells while sparing healthy tissue. It is for men with intermediate-risk prostate cancer that has not spread outside the prostate gland.
Toronto, OntarioAges 50 years+ - NCT06457919RecruitingPhase 1/Phase 2
Tinengotinib with standard treatments for advanced prostate cancer
This study tests a new drug called tinengotinib combined with standard treatments for men with advanced prostate cancer that has stopped responding to abiraterone or enzalutamide. The goal is to see if the combination can help control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT06468332Recruiting
AI learning from MRI and tissue to improve prostate cancer care
This study uses artificial intelligence to look at your MRI scans, tissue samples, and medical records to learn more about prostate cancer and find better ways to treat it. You may join if you've had prostate removal surgery or have advanced prostate cancer.
NovaraAges 18–80 - NCT06474806RecruitingPhase 2
PET scan for untreated prostate cancer
This trial tests a new type of PET scan that looks for a protein called uPAR on prostate cancer cells. It might help doctors see your cancer more clearly without needing surgery or treatment first.
Herlev, CopenhagenAges 18 years+ - NCT06482489Recruiting
Low-field MRI for better prostate imaging
This study tests a new, lower-strength MRI to see if it can give clearer images of the prostate, especially for men who have metal implants or who need a biopsy. It may help doctors monitor prostate health more safely and effectively.
Lausanne, Canton of VaudAges 18 years+
Hear when a new Prostate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate?
- Yes. Clin2 currently lists 1,373 recruiting prostate studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.